Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial
/in Dendritic Cells, Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2012-04-22 / Cancer Immunol. Immunother. 2012 Nov;61(11):2033-44Monitoring of regulatory T cell frequencies and expression of CTLA-4 on T cells, before and after DC vaccination, can predict survival in GBM patients
/in Dendritic Cells, Glioblastoma, International Publications /von 2012-04-02 / PLoS ONE 2012;7(4):e32614Newcastle disease virus triggers autophagy in U251 glioma cells to enhance virus replication
/in Glioblastoma, International Publications, Newcastle Disease Virus /von 2012-03-08 / Arch. Virol. 2012 Jun;157(6):1011-8Clinical application of a dendritic cell vaccine raised against heat-shocked glioblastoma
/in Dendritic Cells, Glioblastoma, International Publications /von 2012-01-01 / Cell Biochem. Biophys. 2012 Jan;62(1):91-9Immunotherapy for glioma: getting closer to the clinical arena?
/in Dendritic Cells, Glioblastoma, International Publications /von 2011-12-01 / Curr. Opin. Neurol. 2011 Dec;24(6):641-7Therapeutical doses of temozolomide do not impair the function of dendritic cells and CD8+ T cells
/in Dendritic Cells, Glioblastoma, International Publications /von 2011-11-23 / Int. J. Oncol. 2012 Mar;40(3):764-72Adjuvant immunotherapy with whole-cell lysate dendritic cells vaccine for glioblastoma multiforme: a phase II clinical trial
/in Dendritic Cells, Glioblastoma, International Publications /von 2011-11-07 / World Neurosurg 2012 May-Jun;77(5-6):736-44Immunotherapy in human glioblastoma
/in Dendritic Cells, Glioblastoma, International Publications /von 2011-08-31 / Rev. Neurol. (Paris) 2011 Oct;167(10):668-72Treatment of high-grade glioma in children and adolescents
/in Dendritic Cells, Glioblastoma, International Publications /von 2011-07-22 / Neuro-oncology 2011 Oct;13(10):1049-58
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution